



Risk of thromboembolism in patients developing critical illness-associated atrial fibrillation

Journal:	<i>Clinical Medicine</i>
Manuscript ID	CM-2017-0371.R1
Manuscript Type:	Original research
Keywords:	Atrial fibrillation, Stroke, Thromboembolism, Intensive care, Critical care

SCHOLARONE™
Manuscripts

Pre-View Only

RISK OF THROMBOEMBOLISM IN PATIENTS DEVELOPING CRITICAL ILLNESS-ASSOCIATED ATRIAL FIBRILLATION

Abstract

Although common, the long-term significance of developing atrial fibrillation (AF) during a period of critical illness is unclear. We undertook a retrospective cohort analysis to assess the rate of thromboembolism (TE) in patients developing atrial fibrillation *de novo* during admission to our intensive care unit. 1955 patients were followed up (maximum follow-up 1276 days) for the occurrence of TE, of which 220 (11.3%) had developed AF or atrial flutter during their critical care admission. There were 11 TE events among the patients with new AF (0.053 events per patient-year), compared with 18 in the non-AF group (0.0059 events per patient-year). The unadjusted hazard ratio for TE in patients developing new AF compared with those not developing AF was 8.09 (95% CI 3.08 – 17.19, $p < 0.001$). In patients admitted to critical care, the development of AF appears to be associated with a significantly increased risk of subsequent thromboembolism.

Key words

Atrial fibrillation, critical care, intensive care, critical illness, stroke, thromboembolism

Introduction

Atrial fibrillation (AF) is prevalent in acute illness, representing the commonest arrhythmia in critical care settings,¹ occurring in 10-15% of patients. The physiological insult of acute illness, altered sympathetic tone or inflammation^{2,3} have all been proposed as triggers. The development of AF in this situation is a poor prognostic sign,⁴ particularly in severe sepsis, where it is associated with a two-fold increase in the risk of death over comparable patients who remain in sinus rhythm.³ Its prevalence, treatment and implications for mortality have therefore been extensively studied in this setting.

In the general population AF confers significant risk of ischemic stroke,⁵ with clear international consensus about anticoagulant prophylaxis in all but the lowest-risk patients.⁶ The thromboembolic (TE) implications of AF arising during acute illness are less well studied⁷ and generally time-limited to the acute phase or hospital stay.^{8,9} Patients in the general population experiencing paroxysmal AF carry equivalent risk to those with persistent or permanent AF¹⁰ and paroxysmal AF is common in patients with apparently idiopathic stroke.^{11,12} Furthermore it is unclear if the TE risk of AF occurs due to the arrhythmia itself, or associated inflammatory or metabolic processes, such that the ephemeral nature of an arrhythmia may be falsely reassuring.

Critical illness brings a plethora of intrinsic and iatrogenic stimuli for arrhythmogenesis, which are more transient than traditional risk factors, but limited evidence suggests important short- and longer-term risk nonetheless.⁹ This study therefore sought to assess the risk of thromboembolism following critical illness-associated AF arising in our intensive care unit (ICU).

Methods

The study was undertaken at a single, large, UK teaching hospital with tertiary specialties. The critical care unit comprises 13 general intensive care beds, nine for neurosurgery/trauma and additional

1
2 high-dependency capacity. A separate cardiothoracic ICU provides peri-operative care for cardiac
3
4 surgery and was not included in this study.
5
6
7

8 An electronic patient record system (Innovian, Dräger Medical, Germany) maintains real-time
9
10 recording of vital statistics and note-keeping. Heart rhythm is manually inputted hourly and acute
11
12 rhythm changes are flagged by nursing staff, with 12-lead electrocardiograms recorded electronically
13
14 for physician review. Patients have electronic pro forma completed at admission and discharge. An
15
16 independently populated electronic discharge record is used for all hospital admissions. A Picture
17
18 Archiving and Communication System (PACS) contains all imaging studies and reports. Letters from
19
20 outpatient clinic visits are recorded on central, computer databases. The patient administration
21
22 system (PAS) records all hospital episodes including admissions, clinic attendances and deaths.
23
24
25

26
27 The electronic records of all patients admitted to our ICU from September 2009 to September 2011
28
29 were screened for the onset of AF or atrial flutter of at least 30 seconds duration during their
30
31 admission. Exclusion criteria included patients with previously documented atrial arrhythmia, those
32
33 known to have had heart valve surgery or with significant mitral valve disease,^{13,14} patients admitted
34
35 to or discharged from ICU on therapeutic anticoagulation, and those <18 years old. Patients resident
36
37 outside the hospital catchment area, where follow up could not be reliably conducted, were also
38
39 excluded. Where patients were admitted to ICU more than once in the study period, the episode in
40
41 which AF was first documented was used as the index admission.
42
43
44

45
46 Baseline characteristics and episode details (including length of ICU stay, death and place of death if
47
48 relevant, and illness severity described by Acute Physiology and Chronic Health Evaluation II
49
50 (APACHE II) score¹⁵) were recorded. The occurrence of TE (stroke, transient ischaemic attack or
51
52 systemic embolism) and presence of risk factors (heart failure, hypertension, age, diabetes mellitus,
53
54 previous systemic TE, vascular disease, gender) were identified based on previously described
55
56 definitions¹⁴ and a CHADS₂VASc score was calculated. TE complications were only included in the
57
58
59

1
2 analysis if they occurred after both the onset of AF and admission to critical care, and were
3
4 diagnosed by a consultant physician, or confirmed with appropriate imaging, or operative or post-
5
6 mortem examination. Where there was any doubt as to the occurrence of an event, this was
7
8 included as an event in the non-AF group, but excluded in the AF group.
9

10
11
12 Follow-up was conducted from the date of onset of AF, or the date of admission to the intensive
13
14 care unit in patients who did not develop AF, to the earliest of: date of death, date of commencing
15
16 therapeutic oral anticoagulation, or termination of study follow-up.
17
18

19 20 21 *Objectives and analyses*

22
23 The objective was to describe the rate of TE complications in patients developing new onset AF (or
24
25 atrial flutter) in the context of acute illness or injury, in a general ICU, compared to those without AF.
26
27

28
29 We used descriptive statistics to describe the baseline characteristics of the patient population.
30

31
32 Categorical variables were expressed as numbers (percentages). Continuous variables were
33
34 expressed as means (standard deviation) or medians (25th, 75th percentiles). Event rates were
35
36 described as both absolute values and per patient-year in both AF and non-AF groups. We used
37
38 Kaplan-Meier estimates to show probability of TE in the two groups and Cox proportional hazards
39
40 models to analyse time to TE. We used Kaplan-Meier estimates and a log-rank test to compare
41
42 mortality between the two groups and Cox proportional hazards (PH) models to analyse time to
43
44 death. For the main outcome; time to TE, as well as for mortality, unadjusted analysis was based on
45
46 a Cox PH model including group (AF or non-AF) as a single predictor variable. The participant
47
48 baseline characteristics age, gender, CHADS₂VASc score and APACHE II score were included as
49
50 covariates in separate Cox models and any found to be individually significantly associated with the
51
52 outcome were included as confounders in an adjusted Cox PH model. Results are reported as
53
54 estimated hazard ratios (HR), with 95% confidence intervals and p-values. All analyses were
55
56 conducted using statistical software R (version 3.3.2).¹⁶
57
58
59
60

Ethical review

The project was reviewed by our institutional review board and registered locally as a clinical audit. Further ethical review and the need for informed consent were waived. Identifiable patient data were utilised only to facilitate the cross referencing of data sources and records were otherwise anonymous. The study was conducted retrospectively, patients were not involved in its conduct and there was no impact on their care.

Results

From September 2009 to September 2011, there were 3625 admissions to critical care, comprising 3078 individuals. After exclusions, 1955 patients were included in the analysis (Figure 1). 220 (11.3%) of these developed AF or atrial flutter during their critical care admission. The baseline characteristics of both groups are described in Table 1.

Thromboembolic events

There were 11 TEs in patients with new onset AF (0.053 events per patient-year; mean follow-up 344 days) and 18 events in those without (0.0059 events per patient-year; mean follow-up 638 days). In the AF group, one patient suffered ischaemic bowel and the remainder had thrombotic strokes or transient ischaemic attacks. Two patients suffered watershed cerebral infarcts following subarachnoid haemorrhage and one during a carotid endarterectomy, all in the group without AF.

At one year, Kaplan-Meier estimates of the probability of TE were 0.081 (95% CI 0.03 – 0.13) in the AF group, compared with 0.008 (95% CI 0.003 – 0.013) in the no AF group. At three years, these estimates were 0.097 (95% CI 0.037 – 0.152) and 0.015 (95% CI 0.008 – 0.023), respectively (Figure 2).

1
2 Cox regression analysis showed strong evidence of an effect of new onset AF on time to occurrence
3
4 of TE. Fitting a model with a single predictor variable for new onset AF, the estimated hazard ratio
5
6 for TE in patients with new onset AF compared to those without was 8.09 (95% CI 3.08 – 17.19,
7
8 $p < 0.001$). The baseline characteristics CHADS₂VASc score, APACHE II score and age were found to be
9
10 individually associated with occurrence of TE and so an adjusted analysis consisted of a Cox
11
12 regression model including a variable for new onset AF and for CHADS₂VASc score, APACHE II score
13
14 and age as possible confounding variables. This gave an estimated adjusted hazard ratio for TE (new
15
16 onset AF/no new AF) 5.91 (95% CI 2.60 – 13.44, $p < 0.001$).

21 *Mortality*

22
23 The mortality rate for the total follow up period was 61.8% (136/220) in the group with new AF
24
25 compared to 33.9% (589/1735) in the group without. Analysis of time-to-death showed evidence of
26
27 increased mortality among patients developing new AF, compared to those who did not ($p < 0.001$,
28
29 log-rank test). At one year, Kaplan-Meier estimates of survival were 0.45 (95% CI 0.38 – 0.52) in the
30
31 AF group, compared with 0.72 (95% CI 0.70 – 0.74) in the no AF group. At three years, these
32
33 estimates were 0.35 (95% CI 0.28 – 0.42) and 0.64 (95% CI 0.62 – 0.67), respectively. In-hospital
34
35 mortality rates were 47.7% (105/220) and 19.3% (335/1735), respectively. Of those with AF, 80 died
36
37 in ICU (36.4%) compared to 228 (13.1%) of those without. Three patients died in hospital on the
38
39 same admission following a TE event; all had developed new onset AF. Cox regression analysis
40
41 showed strong evidence of an effect of new onset AF on mortality. Fitting a model with a single
42
43 predictor variable for new onset AF, the estimated hazard ratio for mortality in patients with new
44
45 onset AF compared to those without was 2.47 (95% CI 2.05 – 2.97, $p < 0.001$). The baseline
46
47 characteristics CHADS₂VASc, APACHE II, gender and age were found to be individually associated
48
49 with mortality and so an adjusted analysis consisted of a Cox regression model including a variable
50
51 for new onset AF and for CHADS₂VASc, APACHE II, gender and age as possible confounding variables.
52
53 This gave an estimated hazard ratio for mortality (new onset AF/no new AF) of 1.53 (95% CI 1.26 –
54
55 1.87, $p < 0.001$).

Discussion

This study suggests that, rather than being simply an inevitable consequence of a physiological insult, the onset of AF or flutter in the acutely ill patient is associated with an increased risk of TE complications. This risk appears to persist and may exceed that seen in the general population.¹⁴

The rate of in-hospital death in patients with AF was high in our study, a known association particularly in sepsis,^{3,4,9} and this finding is likely to reflect disease severity.¹⁷

The association of AF with critical illness is well established¹ and appears common to all acute illness – medical patients in intensive care develop AF around day one or two, similar to trauma^{18,19} and post-operative patients.²⁰ The pathophysiology of AF and aetiology of thrombosis in this context are not completely understood.²¹ Inflammatory mediation has been proposed; acute-onset AF triggers platelet activation and monocyte interaction within minutes²² and platelets continue to express CD40 some weeks after successful cardioversion.²³ Although the cause-effect relationship is debated, this might explain the high rates of AF and TE, although it is not clear whether inflammation, or some other pathology,²⁴ persists to maintain TE risk over the duration we have observed.

Limitations and other studies

The major limitation of this study is its retrospective nature, with inherent difficulty verifying data accuracy. Although multiple sources were cross-referenced, potentially important data such as primary care records have not been examined, with the assumption that all thromboembolic complications would be referred for specialist assessment. We included patients with AF on the first day of their critical care admission if this had not been previously documented, presuming that the illness necessitating their admission also precipitated their AF, whereas it may have been present before. Pragmatically, these patients would usually be considered as having new onset AF and this

1
2 does not materially alter the clinical question therefore. The small numbers of events in either group
3
4 limits multivariable analysis, although the large difference between groups and concordance with
5
6 other, previous studies does provide some confidence.
7
8
9

10 Anticoagulation may confound the risk assessment and follow-up of patients. Prophylaxis of venous
11
12 thrombosis is standard practice for all critically ill patients without a clear contraindication and may
13
14 have reduced the risk of in-hospital TE. Our omission of primary care data also risks failing to identify
15
16 patients with AF who began anticoagulation in the community at a later date, although we would
17
18 expect this to reduce the event rate in the AF group. Thus, if such patients were excluded this may
19
20 actually increase the observed difference. Further limitations include the high exclusion rate for
21
22 patients out of area, which was necessary to optimise the accuracy of follow-up, and the single
23
24 centre nature of this analysis.
25
26
27
28

29 Most prior assessment of this issue occurred via small, short-term studies.^{7,8} Recently however, one
30
31 group has undertaken a number of large, population-based, epidemiological studies exploring the
32
33 association of new-onset AF with sepsis. Walkey et al. used hospital claims data to demonstrate a
34
35 2.6% risk of in-hospital stroke and 2.0% risk of readmission with stroke (non-significant trend) within
36
37 the same year, highlighting the potential TE risk of new onset AF for the first time.⁹ A subsequent
38
39 study of Medicare beneficiaries identified an increase in ischaemic stroke at 5 years from an
40
41 admission with sepsis (5.3% in those with new-onset AF vs. 4.7% without; HR, 1.22; 95% CI, 1.15 –
42
43 1.47)²⁵. These studies acknowledge the limitations of claims data, particularly with regards to coding
44
45 and the temporal association of triggers and events. This current study supports these previous
46
47 analyses by providing, for the first time on this scale, patient-level analysis of all admissions through
48
49 a critical care unit, incorporating history, physiological parameters, diagnoses and investigations.
50
51
52
53

54 One further study has considered the predictive value of CHADS₂ and CHADS₂VASc scoring in the
55
56 general critical care population.²⁶ However, 25% of patients had a history of atrial arrhythmia pre-
57
58
59
60

1
2 dating their critical illness and 9% experienced atrial tachycardia, which is not universally accepted as
3
4 a risk factor for thromboembolism. In the six months of follow up there were 12 recorded
5
6 'thromboembolic' complications, including two myocardial infarctions and four patients with
7
8 documented left atrial appendage thrombus without embolic sequelae. Finally, the use of
9
10 anticoagulation beyond the critical care stay was not considered.
11
12
13

14 *Future questions and research*

15
16 The implication for patients outside critical care environments is less clear. Although AF is commonly
17
18 precipitated by acute illness the illness severity and subsequently high mortality rates in our patients
19
20 may be different to the overall hospital population, and differences in the use and availability of
21
22 critical care facilities may limit the applicability of these findings to other countries. There are a
23
24 plethora of aetiological factors for both AF and TE associated with critical illness,²⁷ including
25
26 inflammation, septic emboli, fluid shifts, and cardiac and vasoactive pharmacotherapy, which may
27
28 be relevant for the prevention and management of both AF and TE, in addition to pre-existing
29
30 comorbidities.^{27,28} We have demonstrated association rather than causality, and further research is
31
32 needed to establish whether the physiological insult of critical illness itself, or its management,
33
34 present an independent risk of future TE. The true implication for all patients with critical illness will
35
36 only be clarified with larger, prospective study.
37
38
39
40
41

42 AF is common following cardiothoracic surgery with a stroke risk of 2-5%.^{29,30} One systematic review
43
44 found no AF-reduction strategy that significantly reduced the risk of stroke.²⁹ As with the general
45
46 population,¹⁰ aggressive rhythm control does not mitigate the risk of TE, although anticoagulation
47
48 post-surgery may.³¹ Large epidemiological studies of the management of AF in critical care imply
49
50 reticence to use anticoagulants in the acute phase due to the risk of haemorrhage^{26,28} and lack of
51
52 short term efficacy.³² These findings reflect the general AF population, where longer term
53
54 anticoagulation, and not rhythm control, is protective against TE. This will need to be carefully
55
56 considered in future strategies for the reduction of TE in these patients.
57
58
59
60

Conclusion

This study suggests that the onset of AF, or atrial flutter, during critical illness may be associated with longer term risk of systemic thromboembolism. Whether the occurrence of AF is causative, or a marker of increased risk, is not clear and similarly the role of mediators such as hypertension need further scrutiny, but the risk of TE appears to persist beyond the period of acute illness. Further, prospective, multi-centre analysis of this association is urgently required.

What is already known about this subject?

- AF is the commonest arrhythmia in critical care environments and its development during critical illness is associated with a worse prognosis
- In the general population, the development of even paroxysmal AF is associated with an increased risk of systemic thromboembolism

What does this study add?

- The development of *de novo* AF during a period of critical illness is associated with an increased longer term risk of systemic thromboembolism

How might this impact on clinical practice?

- There is urgent need to establish the long term risk to patients who have experienced AF during an acute illness
- Strategies for risk assessment and possibly long term anticoagulation need to be considered
- Further consideration of the pathogenesis of thromboembolism in AF, and the relationship between cardiac arrhythmia and systemic processes, is warranted

References

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 1 Annane D, Sébille V, Duboc D, *et al.* Incidence and prognosis of sustained arrhythmias in critically ill patients. *Am J Respir Crit Care Med* 2008;**178**:20–5. doi:10.1164/rccm.200701-031OC
 - 2 Issac TT, Dokainish H, Lakkis NM. Role of Inflammation in Initiation and Perpetuation of Atrial Fibrillation. A Systematic Review of the Published Data. *J. Am. Coll. Cardiol.* 2007;**50**:2021–8. doi:10.1016/j.jacc.2007.06.054
 - 3 Meierhenrich R, Steinhilber E, Eggermann C, *et al.* Incidence and prognostic impact of new-onset atrial fibrillation in patients with septic shock: a prospective observational study. *Crit Care* 2010;**14**:R108. doi:10.1186/cc9057
 - 4 Arora S, Lang I, Nayyar V, *et al.* Atrial fibrillation in a tertiary care multidisciplinary intensive care unit--incidence and risk factors. *Anaesth Intensive Care* 2007;**35**:707–13. <http://www.ncbi.nlm.nih.gov/pubmed/17933156>
 - 5 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke* 1991;**22**:983–8. doi:10.1161/01.STR.22.8.983
 - 6 Camm AJ, Kirchhof P, Lip GYH, *et al.* Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur Heart J* 2010;**31**:2369–429. doi:10.1093/eurheartj/ehq278
 - 7 Sleswijk ME, Van Noord T, Tulleken JE, *et al.* Clinical review: treatment of new-onset atrial fibrillation in medical intensive care patients--a clinical framework. *Crit Care* 2007;**11**:233. doi:10.1186/cc6136
 - 8 Salman S, Bajwa A, Gajic O, *et al.* Paroxysmal atrial fibrillation in critically ill patients with sepsis. *J Intensive Care Med* 2008;**23**:178–83. doi:10.1177/0885066608315838
 - 9 Walkey AJ, Wiener RS, Ghobrial JM, *et al.* Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. *JAMA* 2011;**306**:2248–54. doi:10.1001/jama.2011.1615

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 10 Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: Report from the Stockholm Cohort of Atrial Fibrillation. *Eur Heart J* 2010;**31**:967–75.
doi:10.1093/eurheartj/ehn599
- 11 Flint AC, Banki NM, Ren X, *et al.* Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: The stroke and monitoring for PAF in real time (SMART) registry. *Stroke* 2012;**43**:2788–90. doi:10.1161/STROKEAHA.112.665844
- 12 Rizos T, Güntner J, Jenetzky E, *et al.* Continuous stroke unit electrocardiographic monitoring versus 24-hour holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. *Stroke* 2012;**43**:2689–94. doi:10.1161/STROKEAHA.112.654954
- 13 Gage BF, Waterman AD, Shannon W, *et al.* Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA* 2001;**285**:2864–70. doi:10.1001/jama.285.22.2864
- 14 Lip GYH, Nieuwlaat R, Pisters R, *et al.* Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. *Chest* 2010;**137**:263–72. doi:10.1378/chest.09-1584
- 15 Knaus WA, Draper EA, Wagner DP, *et al.* APACHE II: a severity of disease classification system. *Crit Care Med* 1985;**13**:818–29. doi:10.1097/00003465-198603000-00013
- 16 R Core Team. R: A language and environment for statistical computing. 2016.<https://www.r-project.org/>
- 17 Carrera P, Thongprayoon C, Cheungpasitporn W, *et al.* Epidemiology and outcome of new-onset atrial fibrillation in the medical intensive care unit. *J Crit Care* 2016;**36**:102–6.
doi:10.1016/j.jcrc.2016.06.032
- 18 Seguin P, Laviolle B, Maurice A, *et al.* Atrial fibrillation in trauma patients requiring intensive care. *Intensive Care Med* 2006;**32**:398–404. doi:10.1007/s00134-005-0032-2
- 19 Hadjizacharia P, O’Keeffe T, Brown CVR, *et al.* Incidence, risk factors, and outcomes for atrial

- 1
2 arrhythmias in trauma patients. *Am Surg* 2011;**77**:634–
3
4 9.http://www.ncbi.nlm.nih.gov/pubmed/21679600
5
6
7 20 Heinz G. Arrhythmias in the ICU: what do we know? *Am J Respir Crit Care Med* 2008;**178**:1–2.
8
9 doi:10.1164/rccm.200804-554ED
10
11 21 Guo Y, Lip GYH, Apostolakis S. Inflammation in atrial fibrillation. *J Am Coll Cardiol*
12
13 2012;**60**:2263–70. doi:10.1016/j.jacc.2012.04.063
14
15
16 22 Hayashi M, Takeshita K, Inden Y, *et al.* Platelet activation and induction of tissue factor in
17
18 acute and chronic atrial fibrillation: Involvement of mononuclear cell-platelet interaction.
19
20 *Thromb Res* 2011;**128**:e113-8. doi:10.1016/j.thromres.2011.07.013
21
22
23 23 Duygu H, Barisik V, Kurt H, *et al.* Prognostic value of plasma soluble CD40 ligand in patients
24
25 with chronic non-valvular atrial fibrillation. *Europace* 2008;**10**:210–4.
26
27 doi:10.1093/europace/eum284
28
29
30 24 Wijesurendra RS, Liu A, Eichhorn C, *et al.* Lone Atrial Fibrillation Is Associated With Impaired
31
32 Left Ventricular Energetics That Persists Despite Successful Catheter Ablation. *Circulation*
33
34 2016;**134**:1068–81. doi:10.1161/CIRCULATIONAHA.116.022931
35
36
37 25 Walkey AJ, Hammill BG, Curtis LH, *et al.* Long-term outcomes following development of new-
38
39 onset atrial fibrillation during sepsis. *Chest* 2014;**146**:1187–95. doi:10.1378/chest.14-0003
40
41
42 26 Champion S, Lefort Y, Gaüzère BA, *et al.* CHADS2 and CHA2DS2-VASc scores can predict
43
44 thromboembolic events after supraventricular arrhythmia in the critically ill patients. *J Crit*
45
46 *Care* 2014;**29**:854–8. doi:10.1016/j.jcrc.2014.05.010
47
48
49 27 Makrygiannis SS, Margariti A, Rizikou D, *et al.* Incidence and predictors of new-onset atrial
50
51 fibrillation in noncardiac intensive care unit patients. *J Crit Care* 2014;**29**:697.e1-5.
52
53 doi:10.1016/j.jcrc.2014.03.029
54
55
56 28 Kanji S, Williamson DR, Yaghchi BM, *et al.* Epidemiology and management of atrial fibrillation
57
58 in medical and noncardiac surgical adult intensive care unit patients. *J Crit Care*
59
60

- 1
2 2012;**27**:326.e1-8. doi:10.1016/j.jcrc.2011.10.011
3
4
5 29 Arsenault KA, Yusuf AM, Crystal E, *et al.* Interventions for preventing post-operative atrial
6 fibrillation in patients undergoing heart surgery. *Cochrane database Syst Rev*
7
8 2013;**1**:CD003611. doi:10.1002/14651858.CD003611.pub3
9
10
11 30 Almassi GH, Schowalter T, Nicolosi AC, *et al.* Atrial fibrillation after cardiac surgery: a major
12 morbid event? *Ann Surg* 1997;**226**:501-511-513. doi:10.1097/00000658-199710000-00011
13
14
15 31 Hata M, Akiyama K, Wakui S, *et al.* Does warfarin help prevent ischemic stroke in patients
16 presenting with post coronary bypass paroxysmal atrial fibrillation? *Ann Thorac Cardiovasc*
17
18 *Surg* 2013;**19**:207–11. doi:10.5761/atcs.oa.12.01950
19
20
21 32 Walkey AJ, Quinn EK, Winter MR, *et al.* Practice Patterns and Outcomes Associated With Use
22 of Anticoagulation Among Patients With Atrial Fibrillation During Sepsis. *JAMA Cardiol*
23
24 2016;**1**:682–90. doi:10.1001/jamacardio.2016.2181
25
26
27
28
29
30
31
32
33

34 Figures

35
36 Figure 1: Patient inclusion and exclusion
37
38
39

40 Figure 2: Kaplan-Meier estimates of the probability of thromboembolism in patients with new AF
41 (red line), and in those without new AF (black line). Numbers accompanying the numbers at risk in
42 parentheses are the cumulative number of censored observations.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1

114x88mm (150 x 150 DPI)

Only




Figure 2

177x127mm (300 x 300 DPI)

Table 1 – Baseline characteristics of the study population

	AF (N = 220)	No AF (N = 1735)	Total (N = 1955)
Male, n (%)	137 (62.3)	901 (51.9)	1038 (53.1)
Age, in years, median (25 th , 75 th percentile)	73.0 (64.0, 80.0)	62.0 (47.0, 72.0)	63.0 (49.0, 73.0)
Baseline risk factors, n (%)			
- Heart failure	20 (9.1)	59 (3.4)	79 (4.0)
- Hypertension	110 (50.0)	390 (22.5)	500 (25.6)
- Diabetes mellitus	35 (15.9)	202 (11.6)	237 (12.1)
- Stroke or systemic embolism	24 (10.9)	86 (5.0)	110 (5.6)
- Vascular disease	64 (29.1)	263 (15.2)	327 (16.7)
CHADSVASc score, mean (SD)	2.8 (1.6)	1.7 (1.4)	1.8 (1.5)
APACHE score, mean (SD)	20.7 (7.0)	14.4 (7.2)	15.1 (7.4)

AF = atrial fibrillation; APACHE = Acute Physiology and Chronic Health Evaluation II score; SD = standard deviation